Novartis hedges on when it might submit myelofibrosis drug for approval

feature-image

Play all audios:

LONDON — A Novartis executive on Thursday said “it’s too early to say” whether the company would still submit an experimental myelofibrosis drug for regulatory approval this year, amid


questions about the medicine’s data profile and whether it’s sufficient for filing. Novartis had previously said it planned to submit a marketing application for a rare bone marrow cancer


drug called pelabresib to the Food and Drug Administration this year. But on a call with reporters tied to the company’s second quarter earnings release, Harry Kirsch, the company’s chief


financial officer, said Novartis was awaiting additional, longer-term data that would be available in the coming months.  Novartis picked up pelabresib through its nearly $3 billion


acquisition of the German company MorphoSys, which was announced in February. The deal has closed and Novartis was making progress in absorbing MorphoSys, Kirsch said.  STAT+ Exclusive Story


Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE PHARMA INDUSTRY — BY SUBSCRIBING TO STAT+.


Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe